Search

Your search keyword '"Basuray, Anupam"' showing total 33 results
Start Over Author "Basuray, Anupam"
33 results on '"Basuray, Anupam"'

2. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial

Author

Akar, Joseph, Ando, Jiro, Anzai, Toshihisa, Asakura, Masanori, Bailey, Steven, Basuray, Anupam, Bauer, Fabrice, Bergmann, Martin, Blair, John, Cavendish, Jeffrey, Chung, Eugene, Cikes, Maja, Dauber, Ira, Donal, Erwan, Eicher, Jean-Christophe, Fail, Peter, Flaherty, James, Freixa, Xavier, Gafoor, Sameer, Gertz, Zachary, Gordon, Robert, Guazzi, Marco, Guerrero-Miranda, Cesar, Gupta, Deepak, Gustafsson, Finn, Hadadi, Cyrus, Hakemi, Emad, Handoko, Louis, Hass, Moritz, Hausleiter, Jorg, Hayward, Christopher, Hickey, Gavin, Hummel, Scott, Hussain, Imad, Isnard, Richard, Izumi, Chisato, Jondeau, Guillaume, Juneman, Elizabeth, Kinugawa, Koichiro, Kipperman, Robert, Krakowiak, Bartek, Krim, Selim, Larned, Joshua, Lewis, Gregory, Lipsic, Erik, Magalski, Anthony, Mazimba, Sula, Mazurek, Jeremy, McGrady, Michele, Mckenzie, Scott, Mehta, Shamir, Mignone, John, Morsli, Hakim, Nair, Ajith, Noel, Thomas, Orford, James, Parikh, Kishan, Patterson, Tiffany, Penicka, Martin, Petrie, Mark, Pieske, Burkert, Post, Martijn, Raake, Philip, Romero, Alicia, Ryan, John, Saito, Yoshihiko, Sakamoto, Takafumi, Sakata, Yasushi, Samara, Michael, Satya, Kumar, Sindone, Andrew, Starling, Randall, Trochu, Jean-Noël, Upadhya, Bharathi, van der Heyden, Jan, van Empel, Vanessa, Varma, Amit, Vest, Amanda, Wengenmayer, Tobias, Westenfeld, Ralf, Westermann, Dirk, Yamamoto, Kazuhiro, Zirlik, Andreas, Shah, Sanjiv J, Borlaug, Barry A, Chung, Eugene S, Cutlip, Donald E, Debonnaire, Philippe, Fail, Peter S, Gao, Qi, Hasenfuß, Gerd, Kahwash, Rami, Kaye, David M, Litwin, Sheldon E, Lurz, Philipp, Massaro, Joseph M, Mohan, Rajeev C, Ricciardi, Mark J, Solomon, Scott D, Sverdlov, Aaron L, Swarup, Vijendra, van Veldhuisen, Dirk J, Winkler, Sebastian, and Leon, Martin B

Published
2022
Full Text
View/download PDF

3. PO-03-080 OPTIMIZING POST-IMPLANT CRT MANAGEMENT

Author

Swinning, Jill, primary, Sprott, Kim, additional, Nagle, Katie, additional, Reeser, Tracey, additional, Amin, Anish K., additional, Billakanty, Sreedhar R., additional, Badin, Auroa, additional, Chopra, Nagesh, additional, Fu, Eugene Y., additional, Tyler, Jaret, additional, and Basuray, Anupam, additional

Published
2023
Full Text
View/download PDF

4. A Combined EP & HF APRN Model Can Identify Opportunities In Post-CRT Management

Author

Nagle, Katie, primary, Sprott, Kimberly, additional, Reeser, Tracey, additional, Swinning, Jill, additional, Farley, Marsha, additional, Sherman, Rachel, additional, Rupert, Amanda, additional, Castle, Lindsay, additional, Saha, Naveen, additional, Benatti, Rodolfo Jose Denadai, additional, Dodd, Katherine, additional, Amin, Anish, additional, Billakanty, Sreedhar, additional, and Basuray, Anupam, additional

Published
2023
Full Text
View/download PDF

10. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial

Author

Feldman, Ted, Mauri, Laura, Kahwash, Rami, Litwin, Sheldon, Ricciardi, Mark J., van der Harst, Pim, Penicka, Martin, Fail, Peter S., Kaye, David M., Petrie, Mark C., Basuray, Anupam, Hummel, Scott L., Forde-McLean, Rhondalyn, Nielsen, Christopher D., Lilly, Scott, Massaro, Joseph M., Burkhoff, Daniel, and Shah, Sanjiv J.

Published
2018
Full Text
View/download PDF

12. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II):a randomised, multicentre, blinded, sham-controlled trial

Author

Shah, Sanjiv J., Borlaug, Barry A., Chung, Eugene, Cutlip, Donald E., Debonnaire, Philippe, Fail, Peter, Gao, Qi, Hasenfuß, Gerd, Kahwash, Rami, Kaye, David M., Litwin, Sheldon E., Lurz, Philipp, Massaro, Joseph M., Mohan, Rajeev C., Ricciardi, Mark J., Solomon, Scott D., Sverdlov, Aaron L., Swarup, Vijendra, van Veldhuisen, Dirk J., Winkler, Sebastian, Leon, Martin B., Akar, Joseph, Ando, Jiro, Anzai, Toshihisa, Asakura, Masanori, Bailey, Steven, Basuray, Anupam, Bauer, Fabrice, Bergmann, Martin, Blair, John, Cavendish, Jeffrey, Cikes, Maja, Dauber, Ira, Donal, Erwan, Eicher, Jean Christophe, Flaherty, James, Freixa, Xavier, Gafoor, Sameer, Gertz, Zachary, Gordon, Robert, Guazzi, Marco, Guerrero-Miranda, Cesar, Gupta, Deepak, Gustafsson, Finn, Hadadi, Cyrus, Hakemi, Emad, Handoko, Louis, Hass, Moritz, Shah, Sanjiv J., Borlaug, Barry A., Chung, Eugene, Cutlip, Donald E., Debonnaire, Philippe, Fail, Peter, Gao, Qi, Hasenfuß, Gerd, Kahwash, Rami, Kaye, David M., Litwin, Sheldon E., Lurz, Philipp, Massaro, Joseph M., Mohan, Rajeev C., Ricciardi, Mark J., Solomon, Scott D., Sverdlov, Aaron L., Swarup, Vijendra, van Veldhuisen, Dirk J., Winkler, Sebastian, Leon, Martin B., Akar, Joseph, Ando, Jiro, Anzai, Toshihisa, Asakura, Masanori, Bailey, Steven, Basuray, Anupam, Bauer, Fabrice, Bergmann, Martin, Blair, John, Cavendish, Jeffrey, Cikes, Maja, Dauber, Ira, Donal, Erwan, Eicher, Jean Christophe, Flaherty, James, Freixa, Xavier, Gafoor, Sameer, Gertz, Zachary, Gordon, Robert, Guazzi, Marco, Guerrero-Miranda, Cesar, Gupta, Deepak, Gustafsson, Finn, Hadadi, Cyrus, Hakemi, Emad, Handoko, Louis, and Hass, Moritz

Abstract

Background: Placement of an interatrial shunt device reduces pulmonary capillary wedge pressure during exercise in patients with heart failure and preserved or mildly reduced ejection fraction. We aimed to investigate whether an interatrial shunt can reduce heart failure events or improve health status in these patients. Methods: In this randomised, international, blinded, sham-controlled trial performed at 89 health-care centres, we included patients (aged ≥40 years) with symptomatic heart failure, an ejection fraction of at least 40%, and pulmonary capillary wedge pressure during exercise of at least 25 mm Hg while exceeding right atrial pressure by at least 5 mm Hg. Patients were randomly assigned (1:1) to receive either a shunt device or sham procedure. Patients and outcome assessors were masked to randomisation. The primary endpoint was a hierarchical composite of cardiovascular death or non-fatal ischemic stroke at 12 months, rate of total heart failure events up to 24 months, and change in Kansas City Cardiomyopathy Questionnaire overall summary score at 12 months. Pre-specified subgroup analyses were conducted for the heart failure event endpoint. Analysis of the primary endpoint, all other efficacy endpoints, and safety endpoints was conducted in the modified intention-to-treat population, defined as all patients randomly allocated to receive treatment, excluding those found to be ineligible after randomisation and therefore not treated. This study is registered with ClinicalTrials.gov, NCT03088033. Findings: Between May 25, 2017, and July 24, 2020, 1072 participants were enrolled, of whom 626 were randomly assigned to either the atrial shunt device (n=314) or sham procedure (n=312). There were no differences between groups in the primary composite endpoint (win ratio 1·0 [95% CI 0·8–1·2]; p=0·85) or in the individual components of the primary endpoint. The prespecified subgroups demonstrating a differential effect of atrial shunt device treatment on hea

Published
2022

15. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial

Author

Shah, Sanjiv J, primary, Borlaug, Barry A, additional, Chung, Eugene S, additional, Cutlip, Donald E, additional, Debonnaire, Philippe, additional, Fail, Peter S, additional, Gao, Qi, additional, Hasenfuß, Gerd, additional, Kahwash, Rami, additional, Kaye, David M, additional, Litwin, Sheldon E, additional, Lurz, Philipp, additional, Massaro, Joseph M, additional, Mohan, Rajeev C, additional, Ricciardi, Mark J, additional, Solomon, Scott D, additional, Sverdlov, Aaron L, additional, Swarup, Vijendra, additional, van Veldhuisen, Dirk J, additional, Winkler, Sebastian, additional, Leon, Martin B, additional, Akar, Joseph, additional, Ando, Jiro, additional, Anzai, Toshihisa, additional, Asakura, Masanori, additional, Bailey, Steven, additional, Basuray, Anupam, additional, Bauer, Fabrice, additional, Bergmann, Martin, additional, Blair, John, additional, Cavendish, Jeffrey, additional, Chung, Eugene, additional, Cikes, Maja, additional, Dauber, Ira, additional, Donal, Erwan, additional, Eicher, Jean-Christophe, additional, Fail, Peter, additional, Flaherty, James, additional, Freixa, Xavier, additional, Gafoor, Sameer, additional, Gertz, Zachary, additional, Gordon, Robert, additional, Guazzi, Marco, additional, Guerrero-Miranda, Cesar, additional, Gupta, Deepak, additional, Gustafsson, Finn, additional, Hadadi, Cyrus, additional, Hakemi, Emad, additional, Handoko, Louis, additional, Hass, Moritz, additional, Hausleiter, Jorg, additional, Hayward, Christopher, additional, Hickey, Gavin, additional, Hummel, Scott, additional, Hussain, Imad, additional, Isnard, Richard, additional, Izumi, Chisato, additional, Jondeau, Guillaume, additional, Juneman, Elizabeth, additional, Kinugawa, Koichiro, additional, Kipperman, Robert, additional, Krakowiak, Bartek, additional, Krim, Selim, additional, Larned, Joshua, additional, Lewis, Gregory, additional, Lipsic, Erik, additional, Magalski, Anthony, additional, Mazimba, Sula, additional, Mazurek, Jeremy, additional, McGrady, Michele, additional, Mckenzie, Scott, additional, Mehta, Shamir, additional, Mignone, John, additional, Morsli, Hakim, additional, Nair, Ajith, additional, Noel, Thomas, additional, Orford, James, additional, Parikh, Kishan, additional, Patterson, Tiffany, additional, Penicka, Martin, additional, Petrie, Mark, additional, Pieske, Burkert, additional, Post, Martijn, additional, Raake, Philip, additional, Romero, Alicia, additional, Ryan, John, additional, Saito, Yoshihiko, additional, Sakamoto, Takafumi, additional, Sakata, Yasushi, additional, Samara, Michael, additional, Satya, Kumar, additional, Sindone, Andrew, additional, Starling, Randall, additional, Trochu, Jean-Noël, additional, Upadhya, Bharathi, additional, van der Heyden, Jan, additional, van Empel, Vanessa, additional, Varma, Amit, additional, Vest, Amanda, additional, Wengenmayer, Tobias, additional, Westenfeld, Ralf, additional, Westermann, Dirk, additional, Yamamoto, Kazuhiro, additional, and Zirlik, Andreas, additional

Published
2022
Full Text
View/download PDF

18. B-PO04-187 CARDIAC RESYNCHRONIZATION THERAPY-HEART FAILURE CLINIC: A NOVEL MODEL OF CARE

Author

Swinning, Jill, primary, Sprott, Kimberly, additional, Reeser, Tracey, additional, Amin, Anish K., additional, Basuray, Anupam, additional, Castle, Lindsay, additional, Chopra, Nagesh, additional, Fu, Eugene Y., additional, Kidwell, Gregory A., additional, Kleman, James M., additional, Nelson, Steven D., additional, Nichols, Allan J., additional, Saha, Naveen, additional, Tyler, Jaret, additional, Billakanty, Saanvi, additional, and Billakanty, Sreedhar R., additional

Published
2021
Full Text
View/download PDF

23. One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial

Author

Shah, Sanjiv J., primary, Feldman, Ted, additional, Ricciardi, Mark J., additional, Kahwash, Rami, additional, Lilly, Scott, additional, Litwin, Sheldon, additional, Nielsen, Chris D., additional, van der Harst, Pim, additional, Hoendermis, Elke, additional, Penicka, Martin, additional, Bartunek, Jozef, additional, Fail, Peter S., additional, Kaye, David M., additional, Walton, Anthony, additional, Petrie, Mark C., additional, Walker, Niki, additional, Basuray, Anupam, additional, Yakubov, Steven, additional, Hummel, Scott L., additional, Chetcuti, Stanley, additional, Forde-McLean, Rhondalyn, additional, Herrmann, Howard C., additional, Burkhoff, Daniel, additional, Massaro, Joseph M., additional, Cleland, John G. F., additional, and Mauri, Laura, additional

Published
2018
Full Text
View/download PDF

27. Bacterial Lipopolysaccharide Enhances Cardiac Dysfunction but Not Retroviral Replication in Murine AIDS : Roles of Macrophage Infiltration and Toll-Like Receptor 4 Expression

Author

Chaves, Alysia A., Baliga, Reshma S., Mihm, Michael J., Schanbacher, Brandon L., Basuray, Anupam, Liu, Cynthia, Cook, Angela C., Ayers, Leona W., and Bauer, John Anthony

Subjects
Lipopolysaccharides, Acquired Immunodeficiency Syndrome, Macrophages, Myocardium, Antigens, Differentiation, Myelomonocytic, Heart, Virus Replication, Immunohistochemistry, Original Research Paper, Toll-Like Receptor 4, Disease Models, Animal, Mice, Retroviridae, Antigens, CD, Leukocytes, Animals, Cardiomyopathies
Abstract

Cardiovascular disease is an important complication of human immunodeficiency virus/acquired immune deficiency syndrome (AIDS), but the mechanism(s) involved are poorly understood. Although co-infecting pathogens have been implicated as an important factor in AIDS progression, no studies have investigated these interactions in cardiac tissue. We recently demonstrated that the murine AIDS model (LPBM5 retroviral infection) mimics human immunodeficiency virus-related cardiac dysfunction and pathology. We tested the hypothesis that subseptic lipopolysaccharide exposure (LPS) would enhance LPBM5 progression and exacerbate cardiovascular dysfunction during murine AIDS development. LPS (5 mg/kg, Escherichia coli 0111:B4) was administered at 1, 6, and 8 weeks during LPBM5 infection, and cardiac performance was evaluated at 10 weeks using noninvasive echocardiography. LPS alone had no significant effects, whereas it amplified abnormalities in cardiac structure and function observed in murine AIDS. Cardiac dysfunction was associated with selective increases in nonfocal infiltration of CD68(+) cells and correlated with the extent of cardiac dysfunction. Retroviral progression and cardiac retroviral content remained unaltered, but cardiac toll-like receptor 4 was increased in retrovirus + LPS. We provide first-time evidence of multipathogen enhancements to retrovirus-related cardiac complications and implicate innate immune responses, not co-pathogen-induced retroviral replication, as the primary mechanism in this setting.

Published
2006

28. Heart Failure With Recovered Ejection Fraction

Author

Basuray, Anupam, primary, French, Benjamin, additional, Ky, Bonnie, additional, Vorovich, Esther, additional, Olt, Caroline, additional, Sweitzer, Nancy K., additional, Cappola, Thomas P., additional, and Fang, James C., additional

Published
2014
Full Text
View/download PDF

30. A Shocking Front Nine

Author

Basuray, Anupam, primary, Chamie, Daniel, additional, Asher, Elad, additional, Jozic, Joseph, additional, and Parikh, Sahil A., additional

Published
2012
Full Text
View/download PDF

33. Cardiomyopathy in a murine model of AIDS: evidence of reactive nitrogen species and corroboration in human HIV/AIDS cardiac tissues

Author

Chaves, Alysia A., Mihm, Michael J., Schanbacher, Brandon L., Basuray, Anupam, Liu, Cynthia, Ayers, Leona W., and Anthony Bauer, John

Subjects
CARDIOMYOPATHIES, HIV infections, RETROVIRUS diseases
Abstract

Objective: Cardiomyopathy and other vascular complications are now recognized as significant components of HIV/AIDS pathogenesis. Although the mechanisms involved in cardiomyopathy are poorly defined, a role for direct retroviral action and/or focal infiltration of activated immune cells have been postulated. Here we investigated mechanisms in retrovirus associated cardiomyopathy using a well-defined mouse model of acquired immunodeficiency. Methods: Mice were dosed with LPBM5 retrovirus; cardiac performance was assessed by echocardiography followed by tissue collection at 5 and 10 weeks post-infection. Results: Contractile deficits were observed at 5 and 10 weeks post-retrovirus infection and preceded the development of overt immunodeficiency. Selective and widespread cardiac infiltration of CD68+ cells, but not neutrophils, mast cells, or eosinophils was also observed at both 5 and 10 weeks. LPBM5 retrovirus was readily detectable in cardiac samples by RT-PCR. Time dependent increases in cardiac protein nitration (biomarker of reactive nitrogen species) were observed and were correlated to the extent of cardiac dysfunction whereas no changes in NOSII occurred at 5 and 10 weeks. We corroborated the mouse findings using cardiac tissues and clinical findings from human HIV/AIDS autopsies. Conclusions: These studies demonstrated that cardiac myocyte protein nitration in AIDS related cardiomyopathies, rather than focal immune cell lesions characterize retrovirus associated cardiomyopathies and differentiate them from non-retroviral cardiomyopathies. [Copyright &y& Elsevier]

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results